G2GBIO Surges; Noul, FutureChem Hit Price Limits [K-Bio Pulse]
Predicted impact: Low
Market roundup noting FutureChem hit its daily price limit; no company-specific filing.
FutureChem퓨쳐켐
220100 · KOSDAQ · ₩220100 · 퓨쳐켐
₩8,080▼ ₩340 (4.04%)End-of-day · Oct 28, 2026 · End-of-day prices.
Price · 1Y −48.48%
- Market cap
- ₩250B
- Enterprise value
- ₩238B
- P/E
- —
- P/B
- 4.6×
- Dividend yield
- 0.0%
- ROE
- −20.3%
- Net margin
- −54.1%
Trailing 12 months from filed financial statements, as of H1 2026. Dividend yield: the 2025 dividend per share from the annual report ÷ today's price.
52-week range−72.3% from the high
₩5,342Today: ₩7,940 – ₩8,550₩29,209
Returns
- 1W+13.8%
- 1M+16.4%
- 3M+40.1%
- 6M−49.0%
- YTD−68.6%
- 1Y−48.5%
- Volume today
- 313,560
- 1.4× the 20-day average
- Traded today
- ₩2.6B
- Listed shares
- 30,979,654
- EPS (12 months)
- −₩360
- Earnings yield −4.5%
AI researchResearch being writtenOur AI is writing a report on this company from filed data, prices and news. Check back soon.
Upcoming dates
Full calendar →🎁 Gift this stock
Send a friend ₩100,000 of paper money in this stock. They get it when they join.
Signals
Normal- BuzzNormalBuzz 48 of 100 (50 is a normal day for this stock).
- MomentumStrong29.7% over the last month; the price is above its 20-day average.
- News impactSome3 news items and filings in two weeks; 0 rated high impact, 2 medium.
Signals describe activity, not recommendations. Not financial advice.
FutureChem stock overview
FutureChem (퓨쳐켐, KRX: 220100) is listed on KOSDAQ, in the Biotech & Pharma sector. The company develops radiopharmaceuticals, which are peptide compounds labeled with radioactive isotopes that are used to diagnose and treat specific diseases. Its shares closed at ₩8,080 on Oct 28, 2026, down 4.04% on the day, giving it a market value of ₩250B.
Key facts
- Market cap
- ₩250B
- Sector
- Biotech & Pharma
- Latest price change
- −4.04%
- As of
- Oct 28, 2026
- Main business
- The company develops radiopharmaceuticals, which are peptide compounds labeled with radioactive isotopes that are used to diagnose and treat specific diseases.
Quick answers about FutureChem
- What does FutureChem do?
- The company develops radiopharmaceuticals, which are peptide compounds labeled with radioactive isotopes that are used to diagnose and treat specific diseases. Its diagnostic products include tests for prostate cancer, Parkinson's disease, and Alzheimer's disease, and it is developing prostate cancer treatments that target the PSMA protein. The company also designs and manufactures the sCUBE automated synthesis device and related disposable cassettes and reagent kits for producing radiopharmaceuticals, and it operates in South Korea and conducts clinical trials in the United States, Europe, and China.
- What is the market cap of FutureChem?
- The market capitalisation of FutureChem was ₩250B at the close on Oct 28, 2026.
- Who are the largest shareholders of FutureChem?
- According to the latest official filings, the largest reported holders are Ji Dae-yun (12.31%, as of Sep 21, 2026); Park Young-ja (5.41%, as of Sep 21, 2026); National Pension Service (0.76%, as of Dec 31, 2025).
- When is the next earnings report from FutureChem?
- Korean companies rarely announce results dates in advance. Based on when FutureChem filed the same report in past years, its next 3q results is expected around Nov 14, 2026.
- Does the National Pension Service own FutureChem?
- Yes. The National Pension Service held 0.76% of FutureChem shares as of Dec 31, 2025.
Company profile
The company develops radiopharmaceuticals, which are peptide compounds labeled with radioactive isotopes that are used to diagnose and treat specific diseases. Its diagnostic products include tests for prostate cancer, Parkinson's disease, and Alzheimer's disease, and it is developing prostate cancer treatments that target the PSMA protein. The company also designs and manufactures the sCUBE automated synthesis device and related disposable cassettes and reagent kits for producing radiopharmaceuticals, and it operates in South Korea and conducts clinical trials in the United States, Europe, and China.
Written by AI from the company's latest annual report.
- Korean name
- 퓨쳐켐
- Sector
- Biotech & Pharma
- Themes
- Biotech (new drugs)
- CEO
- 지대윤
- Founded
- Aug 2001
- Listed
- Dec 2016
- Listed shares
- 30,979,654
- Fiscal year ends
- Month 12
- Website
- www.futurechem.co.kr
Similar companies
- Samsung Biologics207940 · ₩64T₩1,372,000−0.15%
- Celltrion068270 · ₩44T₩189,800+0.64%
- Alteogen196170 · ₩16T₩223,000+2.06%
- SK biopharmaceuticals326030 · ₩5.9T₩75,200+0.40%
- Yuhan000100 · ₩5.7T₩77,300−3.38%
- HLB028300 · ₩5.4T₩40,650+1.88%
- Hanmi Pharm128940 · ₩4.7T₩369,500+5.42%
- SAM Chun Dang Pharm000250 · ₩4.5T₩190,000+1.28%
Recent news
G2GBIO surges on Novo collaboration hopes; Noul and FutureChem hit upper limit [Bio Stock Picks]
Predicted impact: Medium
Surge on hopes of Novo collaboration; similar rally news on partnerships already reported.
[Stock Consultation Investor Complaints Desk] FutureChem rises on expectations for new drug development following US clinical trial results
Predicted impact: Medium
US clinical trial results lift new-drug hopes; revenue is small versus market value, so expectations drive it.
Recent filings
See all- Major management matter relevant to investorsOct 23, 2026
- 5%+ holding reportSep 21, 2026
- Insider shareholding reportSep 21, 2026
- Insider shareholding reportSep 21, 2026
- Insider shareholding reportSep 21, 2026
Titles in Korean until English translations are added.
Also known as: FutureChem / 퓨쳐켐 / 220100 / KRX:220100
Source: KRX statistical information